CHINARES PHARMA (03320): China Resources Boya Bio-pharmaceutical Group achieved a net profit attributable to the parent company of 51.1887 million yuan in the first half of the year, a decrease of 77.28% compared to the same period last year.
China Resources Pharmaceutical (03320) announced that China Resources Boya Biotechnology achieved total operating revenue of 644 million yuan for the six months ended June 30, 2026, a decrease of 36.14% year-on-year; the net profit attributable to shareholders of the listed company was 51.1887 million yuan, a decrease of 77.28% year-on-year; basic earnings per share were 0.1 yuan.
CHINARES PHARMA (03320) announced that China Resources Boya Bio-pharmaceutical Group achieved total operating revenue of RMB 644 million for the six months ending June 30, 2026, a decrease of 36.14% year-on-year; the net profit attributable to shareholders of the listed company was RMB 51.1887 million, a decrease of 77.28% year-on-year; basic earnings per share were RMB 0.10.
Related Articles
NANHUA FUTURES (02691) invested HKD 646,000 on August 21 to repurchase 97,500 shares.
LONGBIO-B (01779) released its interim results, reporting a loss attributable to shareholders of 135 million yuan, an increase of 43.1% year-on-year.
KINGDOM HOLDING (00528) announced its interim results, reporting a net profit of 109 million yuan, reversing its losses from the previous year.
NANHUA FUTURES (02691) invested HKD 646,000 on August 21 to repurchase 97,500 shares.
LONGBIO-B (01779) released its interim results, reporting a loss attributable to shareholders of 135 million yuan, an increase of 43.1% year-on-year.
KINGDOM HOLDING (00528) announced its interim results, reporting a net profit of 109 million yuan, reversing its losses from the previous year.
RECOMMEND
